ClinicalTrials.gg
WithdrawnNCT06829199Updated Feb 19, 2026

A Clinical Study of Boserolimab (MK-5890) With Pembrolizumab and Chemotherapy in People With Early Triple-Negative Breast Cancer (MK-5890-003)

A Phase 2 interventional study of Pembrolizumab and Paclitaxel in Early Triple Negative Breast Cancer, sponsored by Merck Sharp & Dohme LLC. Withdrawn at 2 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-02-19.

Sponsored by Merck Sharp & Dohme LLC (part of Merck & Co., Inc) · Phase 2, Interventional, and Treatment

Why this study was withdrawn
Since patients were not recruited yet, we would mark this as a Withdrawn status per the NIH definition of that status. Study halted prematurely, prior to enrollment of first participant.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc — 3 open to participants now, 3 under way, 3 of them phase 3. Triple Negative Breast Neoplasms · Merck & Co., Inc.

Enrollment
17th of 17
0 · median 462
Started
2025
with 3 others
Phase 2
5 of 17
none open now
Registered
14th of 17
by date

Among the 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc, this one is the 17th largest by enrollment, is one of 4 that started in 2025, is one of 5 in phase 2, and was the 14th registered.

Triple Negative Breast Neoplasms

1,219 studies on the registry are indexed under Triple Negative Breast Neoplasms; 445 are open to participants now.

Browse Triple Negative Breast Neoplasms studies →

Open to participants now

3 of the 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 3 open studies →

Who these studies take

Of the 332 Triple Negative Breast Neoplasms studies recruiting now, 232 (70%) set no upper age limit and 85 (26%) stop at 75 or younger; 12 take children under 18; 6 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Triple Negative Breast Neoplasms by Merck & Co., Inc, or all of them as a file.
02

Study summary

Researchers want to learn if giving boserolimab (MK-5890) with standard treatment (pembrolizumab and chemotherapy) before surgery can help treat triple negative breast cancer (TNBC). The goals of this study are to learn about the safety of boserolimab given with standard treatment before surgery and to learn if people tolerate it and how many people have no signs of cancer in the tissues and lymph nodes removed during surgery.

Read the detailed description

The umbrella design of this study provides the framework to evaluate the safety, tolerability and clinical activity of different investigational agents in participants with newly diagnosed, high-risk, early-stage TNBC who might benefit from adding these investigational agents to pembrolizumab plus chemotherapy.

03

Conditions studied

  • Early Triple Negative Breast Cancer

Keywords

  • Triple Negative Breast Cancer
  • Breast cancer
  • Neoadjuvant
  • Boserolimab
  • Pembrolizumab
  • Umbrella study
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

The main inclusion criteria include but are not limited to the following:

  • Has previously untreated high-risk, early-stage, non- (M0) breast cancer (BC), defined as tumor stage T1c, nodal stage N1-2, or tumor stage T2-4, nodal stage N0-2
  • Has provided a core needle for tissue diagnosis of the current breast cancer less than 29 days prior to the date of
  • Has centrally confirmed diagnosis of BC that is triple-negative based on the American Society of Clinical Oncology/College of American Pathologists guidelines
  • Has performance status of 0 or 1 performed within 28 days before treatment randomization
  • Has left ventricle of ≥50% as assessed by echocardiogram or multigated acquisition scan performed at screening
  • Has a history of exposure to anthracycline; participants can be eligible after completion of a Sponsor consultation form, if cumulative lifetime doses are as follows: Doxorubicin \<100 mg/m2, Epirubicin \<180 mg/m2, Mitoxantrone \<40 mg/m2, Idarubicin \<22.5 mg/m2. Note: If another anthracycline or more than one anthracycline has been used, the cumulative dose must not exceed the equivalent of 100 mg/m2 of doxorubicin

Exclusion criteria

Exclusion Criteria:

The main exclusion criteria include but are not limited to the following:

  • Has documented Grade ≥2 peripheral neuropathy
  • Has uncontrolled or significant cardiovascular disease
  • Has received prior therapy with an anti-programmed cell death protein 1 (), anti-programmed cell death-ligand 1 (anti-PD-L1), or anti-PD-L2 agent, or with an agent directed to another stimulatory or coinhibitory T-cell receptor (e.g., cytotoxic T-lymphocyte-associated protein-4 [CTLA-4], OX-40 [cluster of differentiation (CD) 134], or CD137)
  • Has received any prior treatment, including radiation, systemic therapy, and/or definitive surgery for currently diagnosed breast cancer
  • Has received prior systemic anticancer therapy
  • Has undergone excisional of the primary tumor and/or axillary lymph node dissection prior to study treatment
  • Has a diagnosis of immunodeficiency or is receiving chronic systemic therapy or any other form of therapy within 7 days prior to the first dose of study intervention
  • Has a known additional that is progressing or has required active treatment within the past 5 years
  • Has active disease that has required systemic treatment in the past 2 years with need for disease modifying agents such as corticosteroids or immunosuppressive drugs
  • Has history of (noninfectious) pneumonitis/interstitial lung disease that required steroids or has current pneumonitis/interstitial lung disease
  • Has an active infection requiring systemic therapy
  • -infected participants with a history of Kaposi's sarcoma and/or Multicentric Castleman's Disease
  • Has severe (Grade ≥3) to pembrolizumab, any agent or study intervention, any of its , and/or to another biologic therapy
  • Has a history of allogeneic tissue/solid organ transplant
Terms in these criteria, in plain language(14)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Biopsy and archival tissue

A biopsy takes a small piece of tissue to examine. “Archival tissue” is a sample already taken, for example at diagnosis, and kept by the hospital.

Whether a stored sample will do depends on when it was taken, how much there is and what the study needs. Ask whether the study accepts your stored sample or needs a new biopsy.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

LVEF (left ventricular ejection fraction)

The share of blood the heart’s main pumping chamber (the left ventricle) pushes out with each beat, measured by an echocardiogram (heart ultrasound) or a MUGA scan. About 50–70% is normal.

PD-1, PD-L1 and checkpoint inhibitors

PD-1, PD-L1 and CTLA-4 are proteins that act as brakes on the immune system. Checkpoint inhibitors, such as pembrolizumab or nivolumab, block them so the immune system can attack a cancer.

PD-L1 can also be measured in a tumor sample. Some scores count stained tumor cells only (TPS); others also count certain immune cells (CPS). The study names the score and the minimum it uses.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Immunosuppression

A weakened immune system. It can come from an illness, such as HIV or some blood cancers, or from medicines that turn the immune system down, for example after an organ transplant or for an autoimmune disease; steroids at higher doses count.

Read whether the line is about a condition or about medicines, and which medicines and doses it means.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Autoimmune disease

A condition in which the immune system attacks the body’s own tissues, such as rheumatoid arthritis, lupus, psoriasis, type 1 diabetes or inflammatory bowel disease.

Immunotherapy studies often leave out active autoimmune disease, and some name exceptions, such as thyroid disease on replacement hormone. Check the exceptions this study lists.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Excipients

The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
0 participants (actual)

Study arms

  • Active comparator
    Pembrolizumab+ Paclitaxel+ Carboplatin

    Participants will receive pembrolizumab PLUS paclitaxel PLUS carboplatin followed by pembrolizumab PLUS doxorubicin hydrochloride or epirubicin hydrochloride and cyclophosphamide as neoadjuvant therapy prior to surgery. In adjuvant therapy participants will receive pembrolizumab PLUS optional additional adjuvant treatment of physician's choice (TPC), capecitabine or olaparib.

    Biological: Pembrolizumab · Drug: Paclitaxel · Drug: Carboplatin · Drug: Doxorubicin (hydrochloride) · Drug: Epirubicin Hydrochloride · Drug: Cyclophosphamide · Drug: Capecitabine · Drug: Olaparib (if approved/available locally)

  • Experimental
    Pembrolizumab+Boserolimab+Paclitaxel+ Carboplatin

    Participants will receive pembrolizumab PLUS boserolimab PLUS paclitaxel PLUS carboplatin followed by pembrolizumab PLUS doxorubicin hydrochloride or epirubicin hydrochloride and cyclophosphamide PLUS boserolimab as neoadjuvant therapy prior to surgery. In adjuvant therapy participants will receive pembrolizumab PLUS optional additional adjuvant treatment of physician's choice (TPC), capecitabine or olaparib.

    Biological: Pembrolizumab · Drug: Paclitaxel · Drug: Carboplatin · Drug: Doxorubicin (hydrochloride) · Biological: Boserolimab · Drug: Epirubicin Hydrochloride · Drug: Cyclophosphamide · Drug: Capecitabine · Drug: Olaparib (if approved/available locally)

Interventions

  • BiologicalPembrolizumab

    Neoadjuvant therapy - 200 mg intravenous (IV) infusion every 3 weeks (Q3W) for up to approximately 24 weeks Adjuvant therapy - 200 mg IV infusion Q3W or 400 mg IV infusion every 6 weeks (Q6W) for up to approximately 30 weeks.

    Also known as: MK-3475, Keytruda®, SCH 900475

  • 80 mg/m\^2 by IV infusion every week for up to 12 weeks.

  • AUC 1.5 mg/mL/min by IV infusion every week for up to 12 weeks.

  • 60 mg/m\^2 by IV infusion Q3W for up to 12 weeks.

  • BiologicalBoserolimab

    30 mg by IV infusion every 6 weeks (Q6W) for up to 12 Weeks.

    Also known as: MK-5890

  • 90 mg/m\^2 by IV infusion every 3 weeks (Q3W) for up to 12 weeks.

  • 600 mg/m\^2 by IV infusion every 3 weeks (Q3W) for up to 12 weeks.

  • 1000 mg/m\^2 to 1250 mg/m\^2 by oral administration twice a day (2 weeks on and 1 week off) for up to approximately 24 weeks.

  • DrugOlaparib (if approved/available locally)

    Drug page: Olaparib

    300 mg by oral administration twice a day for up to approximately 52 weeks.

06

What researchers measure

Primary outcomes

  1. Number of participants with one or more adverse events (AEs)

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

    Time frame: Up to approximately 34 months

  2. Number of participants who discontinue study intervention due to an AE

    An AE is defined as any unfavorable and unintended sign, symptom, disease, or worsening of preexisting condition temporally associated with study treatment and irrespective of causality to study treatment.

    Time frame: Up to approximately 27 months

  3. Pathological complete response (pCR) rate at the time of definitive surgery

    pCR (ypT0/Tis ypN0) is defined as the absence of residual invasive cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current American Joint Committee on Cancer (AJCC) staging criteria assessed by the local pathologist at the time of definitive surgery.

    Time frame: Up to approximately 9 months

Secondary outcomes

  1. pCR-no ductal carcinoma in situ (DCIS) rate at the time of definitive surgery

    pCR-no ductal carcinoma in situ (DCIS) (ypT0 ypN0) is defined as the absence of residual invasive and in situ cancer on hematoxylin and eosin evaluation of the complete resected breast specimen and all sampled regional lymph nodes after completion of neoadjuvant systemic therapy per current AJCC staging criteria assessed by the local pathologist at the time of definitive surgery.

    Time frame: Up to approximately 9 months

  2. Event-Free Survival (EFS)

    EFS is defined as the time from randomization to disease progression that precludes surgery, local or distant recurrence, or death due to any cause, whichever occurs first.

    Time frame: Up to approximately 72 months

  3. Overall Survival (OS)

    OS is defined as the time from randomization to death due to any cause.

    Time frame: Up to approximately 72 months

07

Study locations

2 sites
  • Optum Care Cancer Center ( Site 0004)
    Las Vegas, Nevada 89102, United States
  • National Cheng Kung University Hospital ( Site 0901)
    Tainan, 704, Taiwan
08

References and documents

Individual participant data

Plan to share: Yes — https://trialstransparency.msdclinicaltrials.com/pdf/ProcedureAccessClinicalTrialData.pdf

Data sharing details ↗ · externaldatasharing-msd.com

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Mar 2025; primary completion for Jan 2029, 45 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 11, 2025
First posted
Feb 17, 2025
StartEst.
Mar 26, 2025
Primary completionEst.
Jan 18, 2029
CompletionEst.
Mar 18, 2031
Last update
Feb 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 19, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06829199
Responsible party
Sponsor
First posted
Feb 17, 2025
Start date
Mar 26, 2025 (estimated)
Primary completion
Jan 18, 2029 (estimated)
Completion
Mar 18, 2031 (estimated)
Last update
Feb 19, 2026

Study contacts

Medical Director
study director · Merck Sharp & Dohme LLC

Oversight

Data monitoring committee
No
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Feb 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Boserolimab

Start the discussion